These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38104333)

  • 41. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer.
    Partain N; Postlewait LM; Teshome M; Rosso K; Hall C; Song J; Meas S; DeSnyder SM; Lim B; Valero V; Woodward W; Ueno NT; Kuerer H; Lucci A
    Ann Surg Oncol; 2021 Aug; 28(8):4265-4274. PubMed ID: 33403525
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aggressive Subsets of Metastatic Triple Negative Breast Cancer.
    Singh J; Asad S; Zhang Y; Nock W; Adams E; Damicis A; Ramaswamy B; Williams N; Parsons HA; Adalsteinsson VA; Winer EP; Lin NU; Partridge AH; Overmoyer B; Stover DG
    Clin Breast Cancer; 2020 Feb; 20(1):e20-e26. PubMed ID: 31631016
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer.
    DeSnyder SM; Mittendorf EA; Le-Petross C; Krishnamurthy S; Whitman GJ; Ueno NT; Woodward WA; Kuerer HM; Akay CL; Babiera GV; Yang W; Lucci A
    Clin Breast Cancer; 2018 Feb; 18(1):e73-e77. PubMed ID: 28755879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.
    Li J; Gonzalez-Angulo AM; Allen PK; Yu TK; Woodward WA; Ueno NT; Lucci A; Krishnamurthy S; Gong Y; Bondy ML; Yang W; Willey JS; Cristofanilli M; Valero V; Buchholz TA
    Oncologist; 2011; 16(12):1675-83. PubMed ID: 22147002
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery.
    Brzezinska M; Williams LJ; Thomas J; Michael Dixon J
    Breast Cancer Res Treat; 2016 Dec; 160(3):387-391. PubMed ID: 27757718
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical outcomes of curative-intent multimodal management of chemorefractory nonmetastatic inflammatory breast cancer.
    Loap P; Nicaise B; Laki F; Loirat D; Pierga JY; Fourquet A; Kirova Y
    Strahlenther Onkol; 2023 Jan; 199(1):30-37. PubMed ID: 35648170
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of inflammatory breast cancer after neoadjuvant chemotherapy.
    Abrous-Anane S; Savignoni A; Daveau C; Pierga JY; Gautier C; Reyal F; Dendale R; Campana F; Kirova YM; Fourquet A; Bollet MA
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1055-63. PubMed ID: 20478662
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer.
    Anfossi S; Giordano A; Gao H; Cohen EN; Tin S; Wu Q; Garza RJ; Debeb BG; Alvarez RH; Valero V; Hortobagyi GN; Calin GA; Ueno NT; Woodward WA; Reuben JM
    PLoS One; 2014; 9(1):e83113. PubMed ID: 24416156
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Usefulness of immediate reconstruction after mastectomy for inflammatory breast cancer with muscle cutaneous flap].
    Aomatsu N; Kawajiri H; Takashima T; Morisaki T; Hirakawa T; Fukuoka T; Kashiwagi S; Nakamura M; Onoda N; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2165-7. PubMed ID: 22202317
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
    Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
    Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases.
    Budach W; Matuschek C; Bölke E; Dunst J; Feyer P; Fietkau R; Haase W; Harms W; Piroth MD; Sautter-Bihl ML; Sedlmayer F; Souchon R; Wenz F; Sauer R;
    Strahlenther Onkol; 2015 Aug; 191(8):623-33. PubMed ID: 25963557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement.
    Cobb AN; Diao K; Teshome M; Lucci A; Ueno NT; Stauder M; Layman RM; Kuerer HM; Woodward WA; Sun SX
    Ann Surg Oncol; 2022 Oct; 29(10):6381-6392. PubMed ID: 35834145
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database.
    Kupstas AR; Hoskin TL; Day CN; Boughey JC; Habermann EB; Hieken TJ
    Br J Surg; 2020 Jul; 107(8):1033-1041. PubMed ID: 32057107
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Distant Metastasis in Patients with Non-Muscle Invasive Bladder Cancer without Local Recurrence : Report of Two Rare Cases].
    Kida K; Shimizu Y; Ogawa K; Kanamaru S; Ito N
    Hinyokika Kiyo; 2018 Jun; 64(6):271-275. PubMed ID: 30064166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Urinary bladder metastasis from primary breast cancer, a rare and challenging diagnosis. A case report and literature review.
    Abdel-Razeq R; AlMasri R; Abunasser M; Edaily S; Jaber O; Khader O; Ghanem R; Abdel-Razeq H
    Ann Med Surg (Lond); 2022 Apr; 76():103455. PubMed ID: 35308426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Once-daily radiation therapy for inflammatory breast cancer.
    Brown L; Harmsen W; Blanchard M; Goetz M; Jakub J; Mutter R; Petersen I; Rooney J; Stauder M; Yan E; Laack N
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):997-1003. PubMed ID: 24721591
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
    Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
    Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Skin thickening as unique pathologic sign of an inflammatory breast cancer: a case report and review of the literature.
    Ballesio L; D'Ambrosio I; Ravazzolo N; Angeletti M; Di Pastena F; Tardioli S; Lodise P; Marini M
    Clin Ter; 2011; 162(4):351-4. PubMed ID: 21912823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Case of a patient with inflammatory breast cancer who responded to preoperative chemotherapy with paclitaxel plus bevacizumab and could subsequently undergo surgery].
    Kashiwagi S; Ishihara S; Ishii M; Asano Y; Watanabe M; Morisaki T; Aomatsu N; Noda S; Kawajiri H; Nakano T; Kawakami N; Mitsukawa Y; Takashima T; Onoda N; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2384-6. PubMed ID: 24394120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.
    Debeb BG; Gong Y; Atkinson RL; Sneige N; Huo L; Gonzalez-Angulo AM; Hung MC; Valero V; Ueno NT; Woodward WA
    J Exp Clin Cancer Res; 2014 Jul; 33(1):58. PubMed ID: 25051981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.